Please assess the completion status of the following clinical trial:

Trial Title: Effect of Fluvastatin on Biomarkers in Women Who Are Undergoing Surgery for Ductal Carcinoma In Situ or Stage I Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed ductal carcinoma in situ (DCIS) or stage I breast cancer by stereotactic core or incisional biopsy~* Planning to undergo surgery in 3-6 weeks~  * Patients undergoing re-excision due to evidence of tumor present at surgical margins are eligible~* Hormone receptor status not specified~PATIENT CHARACTERISTICS:~* Female~* Menopausal status not specified~* ALT and AST ≤ 10% above upper limit of normal~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* Able to tolerate statins~* Willing to undergo 2 blood draws (separated by approximately 3-4 weeks) during study participation (control arm)~PRIOR CONCURRENT THERAPY:~* No other concurrent statins~* No concurrent chemotherapy~* No concurrent administration of any of the following:~  * Niacin~ * Propranolol~ * Cholestyramine~ * Cyclosporine~ * Digoxin~ * Erythromycin~ * Itraconazole~ * Gemfibrozil~ * Phenytoin~ * Diclofenac~ * Tolbutamide~ * Glyburide~ * Losartan~ * Cimetidine~ * Ranitidine~ * Omeprazole~ * Rifampin~ * Warfarin~* No initiation of new hormonal therapy during study participation~* Concurrent participation in other clinical trials (e.g., for DCIS or prevention) is allowed

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients receive oral fluvastatin sodium once daily for 3-6 weeks in the absence of disease progression or unacceptable toxicity.
- Arm II (Type: EXPERIMENTAL): Patients receive oral fluvastatin sodium as in arm I at a higher dose.
- Arm III (Type: EXPERIMENTAL): Patients do not receive fluvastatin sodium. breast Cancer surgery only

Based on this trial design, predict the completion outcome and termination type (if applicable).